1. FDA. CDER Therapeutic Biologic Products. CDER billable biologic product list. http://www.fda.gov/drugs/developmentapprovalprocess/druginnovation/default.htm . Accessed 1 June 2014.
2. FDA. User fee billable biologic products and potencies approved under section 351 of the PHS Act. http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CBER/ucm122936.htm . Accessed 1 June 2014.
3. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov. 2008;7:21–39.
4. FDA. For Industry. Developing products for rare diseases and conditions. http://www.fda.gov/forindustry/DevelopingProductsforrareDiseasesConditions/default.htm . Accessed 1 June 2014.
5. Baldo BA, Pham NH. Drug allergy. Clinical aspects, diagnosis, mechanisms, structure-activity relationships. New York: Springer; 2013.